
Lecanemab’s Rare and Manageable Side Effects
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.

Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.

Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?

See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.

The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.

The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.

ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.

A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.

The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.

Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.

TEEPA CARE VIDEO: Learn about Alzheimer’s 6 stages. Teepa Snow shows what to expect, while keeping the focus on the person for whom you care.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.